Figure 2.

Simvastatin reduced β-catenin expression in human leiomyoma cells. Human leiomyoma cells (HuLM) and primary cells were treated with simvastatin (1uM) for 48 hours. A, Simvastatin significantly reduced the mRNA expression of CNTTB in HuLM cells. B-C, Simvastatin reduced the protein expression of total and nonphosphorylated β-catenin in both HuLM and primary cells as seen in Western blotting and immunohistochemistry. D, Nuclear protein isolation was performed to check nuclear β-catenin level, which is the site of action of the active form of β-catenin. Simvastatin reduced nuclear levels of β-catenin.